Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Allele-Specific Silencing Ameliorates Restrictive Cardiomyopathy Attributable to a Human Myosin Regulatory Light Chain Mutation.

Zaleta-Rivera K, Dainis A, Ribeiro AJS, Cordero P, Rubio G, Shang C, Liu J, Finsterbach T, Parikh VN, Sutton S, Seo K, Sinha N, Jain N, Huang Y, Hajjar RJ, Kay MA, Szczesna-Cordary D, Pruitt BL, Wheeler MT, Ashley EA.

Circulation. 2019 Aug 27;140(9):765-778. doi: 10.1161/CIRCULATIONAHA.118.036965. Epub 2019 Jul 18.

PMID:
31315475
2.

Therapeutic potential of AAV9-S15D-RLC gene delivery in humanized MYL2 mouse model of HCM.

Yadav S, Yuan CC, Kazmierczak K, Liang J, Huang W, Takeuchi LM, Kanashiro-Takeuchi RM, Szczesna-Cordary D.

J Mol Med (Berl). 2019 Jul;97(7):1033-1047. doi: 10.1007/s00109-019-01791-z. Epub 2019 May 17.

PMID:
31101927
3.

The E22K mutation of myosin RLC that causes familial hypertrophic cardiomyopathy increases calcium sensitivity of force and ATPase in transgenic mice.

Szczesna-Cordary D, Guzman G, Zhao J, Hernandez O, Wei J, Diaz-Perez Z.

J Cell Sci. 2005 Aug 15;118(Pt 16):3675-83. Epub 2005 Aug 2.

4.

Hypercontractile mutant of ventricular myosin essential light chain leads to disruption of sarcomeric structure and function and results in restrictive cardiomyopathy in mice.

Yuan CC, Kazmierczak K, Liang J, Kanashiro-Takeuchi R, Irving TC, Gomes AV, Wang Y, Burghardt TP, Szczesna-Cordary D.

Cardiovasc Res. 2017 Aug 1;113(10):1124-1136. doi: 10.1093/cvr/cvx060.

5.

Diastolic dysfunction in familial hypertrophic cardiomyopathy transgenic model mice.

Abraham TP, Jones M, Kazmierczak K, Liang HY, Pinheiro AC, Wagg CS, Lopaschuk GD, Szczesna-Cordary D.

Cardiovasc Res. 2009 Apr 1;82(1):84-92. doi: 10.1093/cvr/cvp016. Epub 2009 Jan 15.

6.

Constitutive phosphorylation of cardiac myosin regulatory light chain prevents development of hypertrophic cardiomyopathy in mice.

Yuan CC, Muthu P, Kazmierczak K, Liang J, Huang W, Irving TC, Kanashiro-Takeuchi RM, Hare JM, Szczesna-Cordary D.

Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):E4138-46. doi: 10.1073/pnas.1505819112. Epub 2015 Jun 29.

7.

Cardiac contractility, motor function, and cross-bridge kinetics in N47K-RLC mutant mice.

Wang L, Kazmierczak K, Yuan CC, Yadav S, Kawai M, Szczesna-Cordary D.

FEBS J. 2017 Jun;284(12):1897-1913. doi: 10.1111/febs.14096. Epub 2017 May 25.

8.

Hypertrophic cardiomyopathy associated Lys104Glu mutation in the myosin regulatory light chain causes diastolic disturbance in mice.

Huang W, Liang J, Kazmierczak K, Muthu P, Duggal D, Farman GP, Sorensen L, Pozios I, Abraham TP, Moore JR, Borejdo J, Szczesna-Cordary D.

J Mol Cell Cardiol. 2014 Sep;74:318-29. doi: 10.1016/j.yjmcc.2014.06.011. Epub 2014 Jun 30.

9.

Cardiac-targeted RNA interference mediated by an AAV9 vector improves cardiac function in coxsackievirus B3 cardiomyopathy.

Fechner H, Sipo I, Westermann D, Pinkert S, Wang X, Suckau L, Kurreck J, Zeichhardt H, Müller O, Vetter R, Erdmann V, Tschope C, Poller W.

J Mol Med (Berl). 2008 Sep;86(9):987-97. doi: 10.1007/s00109-008-0363-x. Epub 2008 Jun 12.

PMID:
18548221
10.

E22K mutation of RLC that causes familial hypertrophic cardiomyopathy in heterozygous mouse myocardium: effect on cross-bridge kinetics.

Dumka D, Talent J, Akopova I, Guzman G, Szczesna-Cordary D, Borejdo J.

Am J Physiol Heart Circ Physiol. 2006 Nov;291(5):H2098-106. Epub 2006 Jun 2.

11.

Myosin regulatory light chain mutation found in hypertrophic cardiomyopathy patients increases isometric force production in transgenic mice.

Kazmierczak K, Muthu P, Huang W, Jones M, Wang Y, Szczesna-Cordary D.

Biochem J. 2012 Feb 15;442(1):95-103. doi: 10.1042/BJ20111145.

12.

Prolonged Ca2+ and force transients in myosin RLC transgenic mouse fibers expressing malignant and benign FHC mutations.

Wang Y, Xu Y, Kerrick WG, Wang Y, Guzman G, Diaz-Perez Z, Szczesna-Cordary D.

J Mol Biol. 2006 Aug 11;361(2):286-99. Epub 2006 Jun 27.

PMID:
16837010
13.

Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy.

Suckau L, Fechner H, Chemaly E, Krohn S, Hadri L, Kockskämper J, Westermann D, Bisping E, Ly H, Wang X, Kawase Y, Chen J, Liang L, Sipo I, Vetter R, Weger S, Kurreck J, Erdmann V, Tschope C, Pieske B, Lebeche D, Schultheiss HP, Hajjar RJ, Poller WC.

Circulation. 2009 Mar 10;119(9):1241-52. doi: 10.1161/CIRCULATIONAHA.108.783852. Epub 2009 Feb 23.

14.

Novel familial dilated cardiomyopathy mutation in MYL2 affects the structure and function of myosin regulatory light chain.

Huang W, Liang J, Yuan CC, Kazmierczak K, Zhou Z, Morales A, McBride KL, Fitzgerald-Butt SM, Hershberger RE, Szczesna-Cordary D.

FEBS J. 2015 Jun;282(12):2379-93. doi: 10.1111/febs.13286. Epub 2015 Apr 16.

15.

Phosphomimetic-mediated in vitro rescue of hypertrophic cardiomyopathy linked to R58Q mutation in myosin regulatory light chain.

Yadav S, Kazmierczak K, Liang J, Sitbon YH, Szczesna-Cordary D.

FEBS J. 2019 Jan;286(1):151-168. doi: 10.1111/febs.14702. Epub 2018 Dec 1.

PMID:
30430732
16.

Cardiac myosin light chain kinase is necessary for myosin regulatory light chain phosphorylation and cardiac performance in vivo.

Ding P, Huang J, Battiprolu PK, Hill JA, Kamm KE, Stull JT.

J Biol Chem. 2010 Dec 24;285(52):40819-29. doi: 10.1074/jbc.M110.160499. Epub 2010 Oct 13.

17.

Pathogenesis of Hypertrophic Cardiomyopathy is Mutation Rather Than Disease Specific: A Comparison of the Cardiac Troponin T E163R and R92Q Mouse Models.

Ferrantini C, Coppini R, Pioner JM, Gentile F, Tosi B, Mazzoni L, Scellini B, Piroddi N, Laurino A, Santini L, Spinelli V, Sacconi L, De Tombe P, Moore R, Tardiff J, Mugelli A, Olivotto I, Cerbai E, Tesi C, Poggesi C.

J Am Heart Assoc. 2017 Jul 22;6(7). pii: e005407. doi: 10.1161/JAHA.116.005407.

18.

Sarcomeric perturbations of myosin motors lead to dilated cardiomyopathy in genetically modified MYL2 mice.

Yuan CC, Kazmierczak K, Liang J, Zhou Z, Yadav S, Gomes AV, Irving TC, Szczesna-Cordary D.

Proc Natl Acad Sci U S A. 2018 Mar 6;115(10):E2338-E2347. doi: 10.1073/pnas.1716925115. Epub 2018 Feb 20.

19.

Myosin regulatory light chain phosphorylation enhances cardiac β-myosin in vitro motility under load.

Karabina A, Kazmierczak K, Szczesna-Cordary D, Moore JR.

Arch Biochem Biophys. 2015 Aug 15;580:14-21. doi: 10.1016/j.abb.2015.06.014. Epub 2015 Jun 25.

20.

Discrete effects of A57G-myosin essential light chain mutation associated with familial hypertrophic cardiomyopathy.

Kazmierczak K, Paulino EC, Huang W, Muthu P, Liang J, Yuan CC, Rojas AI, Hare JM, Szczesna-Cordary D.

Am J Physiol Heart Circ Physiol. 2013 Aug 15;305(4):H575-89. doi: 10.1152/ajpheart.00107.2013. Epub 2013 Jun 7.

Supplemental Content

Support Center